Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Next Previous
Trial Profile

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab/relatlimab (Primary) ; Relatlimab (Primary) ; Zanzalintinib (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Transitional cell carcinoma; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STELLAR-002
  • Sponsors Exelixis

Most Recent Events

  • 12 Feb 2026 Status changed from active, no longer recruiting to recruiting.
  • 20 Jan 2026 Planned number of patients changed from 1274 to 1314.
  • 22 May 2025 Results presented in the Exelixis Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top